In a recent shift of sentiment, Xencor, Inc. (NASDAQ: XNCR) received a Neutral rating from Brian Cheng at JP Morgan on March 24, 2026. This decision comes as the stock currently hovers around $11.89, slightly below its average price target of $20, suggesting a notable upside potential should market conditions favor the biotech firm.
Recent Price Action
Xencor’s stock has seen a degree of volatility over the past few weeks. Currently priced at $11.89, the stock is down $0.16 or approximately 1.33% on the day. Over the last year, XNCR has faced a considerable challenge, trading significantly below its 52-week high of $95.81—reflecting a decline of nearly 87% from its peak. The 52-week low stands at $11.71, highlighting a turbulent trading environment for the biotech sector. With a market capitalization of nearly $872 million, the stock’s beta of 0.999 indicates that it moves in tandem with the market, providing investors some predictability in these volatile times. Recent trading volumes support this sentiment, with 1,230,502 shares changing hands against an average volume of 727,845 shares.
Short- and Long-Term Performance
Xencor’s performance metrics reveal a challenging landscape. Over the past 30 days, the stock has plummeted approximately 20%, indicating immediate headwinds for investors. Meanwhile, the quarterly performance reflects a decline of 14.42%, and the stock has lost 36.89% over the last year. Adding to the market fluctuations, XNCR has recorded a weekly volatility of 6.27% and a monthly volatility of 5.23%. Comparatively, its 10-day average trading volume has surged to 1,169,817, indicating heightened interest or concern from investors.
Earnings and Financials
The company’s current earnings report shows a considerable divergence from expectations. For the latest quarter ending November 5, 2025, Xencor reported an Earnings Per Share (EPS) of -$0.08, significantly better than the estimated -$0.72, leading to an impressive surprise factor of 88.89%. This remarkable variance in earnings suggests that while the company is still in negative territory, underlying business fundamentals may be improving—a point of optimism for potential investors. In contrast, previous quarters have shown a less favorable surprise, with an EPS of -$0.41 against an estimate of -$0.78, underscoring the volatility in earnings quality and predictability.
Analyst and Consensus View
According to consensus ratings over the last 90 days, analysts are cautiously optimistic yet measured regarding Xencor. With two total ratings—one Buy and one Hold—the sentiment reflects a balanced view amidst the volatility. JP Morgan, as the notable analyst firm providing insight, gives a noteworthy price target of $13, aligning with the current trading price. However, the broader average price target of $20, alongside a high estimate of $27, indicates a perceived upside, supported by a lack of Sell ratings in the recent analyst landscape.
Stock Grading and Fundamental View
Xencor has been assigned a Stocks Telegraph Score of 40, indicating midway prospects in its overall health and investment outlook. This score takes into account various financial metrics, market analysis, and recent performance. While the score reflects certain challenges the company faces, it also signals potential for recovery and growth, particularly if positive earnings trends continue.
Conclusion
For investors considering Xencor, this stock appears best suited for growth-oriented portfolios willing to accept a degree of risk. While the technical and performance outlook may raise alarm bells, the impressive earnings surprise and potential alignment with analyst targets suggest that XNCR is worth monitoring closely. However, the significant historical decline and ongoing volatility necessitate vigilance, especially as the company navigates the complexities of the biotech sector. Investors should weigh these dynamics carefully before committing capital, understanding both the risks and the possible reward of an eventual recovery.